Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

79.72
+1.391.77%
Post-market: 79.720.00000.00%19:55 EST
Volume:463.14K
Turnover:37.07M
Market Cap:3.01B
PE:-14.70
High:81.28
Open:79.64
Low:78.75
Close:78.33
52wk High:99.50
52wk Low:30.82
Shares:37.75M
Float Shares:32.58M
Volume Ratio:1.03
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.4247
EPS(LYR):-3.9613
ROE:-34.78%
ROA:-22.61%
PB:5.25
PE(LYR):-20.12

Loading ...

Press Release: CHAMPION IRON REPORTS ITS FY2026 THIRD QUARTER RESULTS AND ADVANCES THE DRPF PROJECT AS PLANNED

Dow Jones
·
Jan 29

Disc Medicine Chief Legal Officer Rahul Khara Reports Disposal of Common Shares

Reuters
·
Jan 22

Assessing Disc Medicine (IRON) Valuation After FDA Review Delay And Heightened Regulatory Focus

Simply Wall St.
·
Jan 18

Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action

Benzinga
·
Jan 17

Disc Medicine: Bitopertin’s Accelerated Approval Path and FDA Timing Support Buy Rating and $118 Target

TIPRANKS
·
Jan 16

EXCLUSIVE-US FDA delays two drug reviews in new voucher program after safety, efficacy concerns

Reuters
·
Jan 16

Sector Update: Health Care Stocks Softer in Afternoon Trading

MT Newswires Live
·
Jan 16

Reported timing of Disc Medicine review date a positive, says Morgan Stanley

TIPRANKS
·
Jan 16

Disc Medicine falls -6.8%

TIPRANKS
·
Jan 16

Analysts Offer Insights on Healthcare Companies: Penumbra (PEN) and Disc Medicine (IRON)

TIPRANKS
·
Jan 16

FDA pushes back reviews of several fast-tracked medicines, Reuters reports

TIPRANKS
·
Jan 15

Disc Medicine selloff brings buying opportunity, says Wedbush

TIPRANKS
·
Jan 15

FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks

Benzinga_recent_news
·
Jan 15

Market Chatter: Sanofi, Disc Medicine Drug Reviews Delayed as FDA Flags Safety, Efficacy Issues

MT Newswires Live
·
Jan 15

Exclusive-FDA Pushes Back Review of Sanofi's Diabetes Drug Tzield and Disc Medicine's Blood Disorder Drug -Documents

THOMSON REUTERS
·
Jan 15

Disc Medicine Inc. i Unveils Hematology Pipeline and Bitopertin Launch Strategy in New Corporate Presentation

Reuters
·
Jan 15

How Disc Medicine’s New HR Chief and Bitopertin Review Could Shape IRON’s Commercial Readiness

Simply Wall St.
·
Jan 14

Disc Medicine Says FDA Engagement Over Bitopertin Remains Productive -- Market Talk

Dow Jones
·
Jan 14

Wedbush Sticks to Their Buy Rating for Disc Medicine (IRON)

TIPRANKS
·
Jan 13

Analysts Have Conflicting Sentiments on These Healthcare Companies: Disc Medicine (IRON), Nuvalent (NUVL) and Roche Holding AG (OtherRHHVF)

TIPRANKS
·
Jan 13